Abstract
Structural bioinformatics plays a crucial role in the drug discovery process by providing insights into the molecular interactions between drugs and their targets. Advances in computational methods, such as molecular docking, molecular dynamics simulations, and homology modeling, have significantly improved the accuracy and efficiency of drug design. This article explores the modern approaches in structural bioinformatics that are transforming drug design, with a focus on the use of computational tools to predict protein-ligand interactions, optimize drug efficacy, and minimize side effects. We also discuss the challenges in the field and the future directions for integrating structural bioinformatics into personalized medicine and drug development.
All articles published in the American Journal of Bioinformatics (AJB) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license, authors retain full copyright of their work and grant permission to anyone to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Conditions:
-
Attribution: Appropriate credit must be given to the original author(s) and the source, a link to the license must be provided, and any changes made must be indicated.
-
No additional restrictions: You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This open-access license ensures that scholarly work published in AJB is freely accessible and usable, promoting knowledge dissemination and academic collaboration worldw